Clinical Trials Logo

Clinical Trial Summary

This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02895906
Study type Interventional
Source Cerecor Inc
Contact
Status Completed
Phase Phase 1
Start date November 28, 2016
Completion date April 20, 2017

See also
  Status Clinical Trial Phase
Terminated NCT04639960 - Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome N/A
Recruiting NCT04373226 - Arithmetic Abilities in Children With 22q11.2DS N/A
Completed NCT01781923 - Cognitive Remediation in 22q11DS N/A
Terminated NCT03284060 - Social Cognition Training and Cognitive Remediation N/A
Recruiting NCT04639388 - Understanding of Psychotic Disorders in Children With 22q11.2DS N/A
Completed NCT00916955 - Genetic Modifiers for 22q11.2 Syndrome
Recruiting NCT05924347 - Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
Recruiting NCT00556530 - Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Completed NCT02460328 - Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome N/A
Completed NCT04647500 - Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome N/A